Optimizing the Management of Acute Myeloid Leukemia: Individualized Therapy

Released On
August 15, 2020

Expires On
August 14, 2021

Media Type

Completion Time
60 minutes



Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Practicing Clinicians Exchange.

This program was developed from a series of programs cosupported by educational grants from Astellas; Astellas and Pfizer; Celgene Corporation; Exelixis; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Pharmacyclics LLC, an AbbVie Company; Sanofi Genzyme; Seattle Genetics; and Verastem Oncology.

This activity is supported by educational grants from Astellas and Celgene Corporation.

Credit Available

  • CE/CME Credit Hours: 1.00
  • Pharmacology Credit Hours: 1.00

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses.

Program Overview

Recently approved agents have expanded the horizon of treatment for acute myeloid leukemia (AML). Most of these newer drugs target specific genetic mutations, AML subsets, or patient populations, which amplifies the importance of determining cytogenetic and molecular profiles and stratifying risk in order to develop individual treatment plans. This activity addresses advances in the treatment of AML, appropriate use of novel therapies, management of therapy-related toxicities, and provides an overview of investigational therapies and maintenance therapy.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe diagnostic testing for risk stratification in AML and the role of cytogenetic and molecular factors in treatment selection
  • Identify individualized AML treatment approaches based on efficacy and safety data, as well as patient- and disease-related characteristics
  • Implement strategies to recognize, monitor, and manage toxicities associated with new agents used in the treatment of AML



Kendra Sweet, MD, MS

Assistant Professor
Department of Oncologic Sciences
University of South Florida
Assistant Member
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida


Accreditation Statement

In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


ANCC Credit Designation
Course director: Lee Schwartzberg, MD, FACP, West Cancer Center, Germantown, Tennessee
CNE course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit


AAPA Credit Designation

Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 14, 2021. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois


IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.



Disclosures of Conflicts of Interest

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Kendra Sweet, MD, MS

  • Advisory Board: Astellas Pharma, Bristol-Myers Squibb, Novartis, Takeda
  • Consultant: Stemline Therapeutics
  • Research Support: Incyte

Lee Schwartzberg, MD

  • Consultant: Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Pfizer, Spectrum

Beth Sandy, MSN, CRNP

  • Speakers Bureau: AstraZeneca, Merck, Takeda

Corinne Williams, PA-C

  • Speakers Bureau: AstraZeneca

None of the members of the PCE staff have any relevant relationships to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Instructions for Participation and Credit

Participants wishing to earn CE/CME credit must:

  1. Read the content in its entirety.
  2. Relate the content material to the learning objectives.
  3. Complete the post-test and evaluation form.
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Contact Information

For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.